Search Results for "poverty guidelines"
Displaying 81 - 100 of 154 results. 20 results shown per page. Page 5 of 8.
CMS — SafeBlood: Interim Response, January 14, 2003
Publication Date
January 14, 2003 Debby Thetford Nye, Esq. Mitchell, Williams, Selig, Gates, and Woodward, P.L.L.C. 5414 Pinnacle Point Drive, Suite 500 Rogers, Arkansas 72758-8131 Dear Ms. Nye:
NIH — Gonzalez Regiment Trial: Interim Response, July 9, 2012
Publication Date
HHS Information Quality Web Site Information Requests for Corrections and HHS' Responses Interim Response [ Full Table of Contents ]
CDC — Fluoroquinolone: Request for Reconsideration (RFR)
Publication Date
March 27, 2003 VIA FEDEX and E-MAIL (w/o Attachments) CDC/ATSDR MASO/MS-E11 1600 Clifton Road, N.E. Atlanta, GA 30333 Information Quality Appeal
CDC/ATSDR — Chesapeake Well Site Health Consultation: Interim Response, July 20. 2012
Publication Date
July 20. 2012 Paul I HagemeierChesapeake Energy CorporationP.O. Box 18496Oklahoma City, OK 73154-0496 Dear Mr. Hagemeier
CDC/ATSDR — Chesapeake Well Site Health Consultation: Interim Response, May 21, 2012
Publication Date
May 21, 2012 Paul HagemeierChesapeake Energy CorporationP.O. Box 18496Oklahoma City, OK 73154-0496 Dear Mr. Hagemeier
NIH — Gonzalez Regiment Trial: Interim Response, May 08, 2012
Publication Date
HHS Information Quality Web Site Information Requests for Corrections and HHS' Responses Interim Response [ Full Table of Contents ]
FDA — Genasense: Interim Response, October 22, 2007
Publication Date
NDA 21-649 Ms. Nancy L. BucMs. Deborah LivorneseBuc & Beardsley919 Eighteenth Street,N.W. Washington, D.C. 20006-5503 Dear Ms. Buc and Ms. Livornese:
CDC/ATSDR — Chesapeake Well Site Health Consultation: Interim Response, March 21, 2012
Publication Date
March 21, 2012 Paul HagemeierChesapeake Energy CorporationP.O. Box 18496Oklahoma City, OK 73154-0496 Dear Mr. Hagemeier
FDA — Genasense: Interim Response, AUG 24, 2007
Publication Date
NDA 21-649 Ms. Nancy L. BucMs. Deborah LivorneseBuc & Beardsley919 Eighteenth Street, N.W.Washington, D.C. 20006-5503 Dear Ms. Buc and Ms. Livornese:
FDA — OMEGA Letter: Interim Response, May 16, 2006
Publication Date
Date: May 16, 2006 Jay Davis, President Omega Laboratories, Inc. RE: Request for Correction (Removal) of Information Found On the OIVD Section of the FDA Web Site Dear Mr. Davis:
NIH — Smokeless Tobacco Ingredients: Interim Response
Publication Date
From: Info Quality (NIH/OD) [mailto:InfoQuality@OD.NIH.GOV] Sent: Thursday, June 01, 2006 6:46 PM To: Roerty, Gerry (RIC) Subject: Request for Reconsideration Submitted by Swedish Match Regarding Smokeless Tobacco Dear Mr. Roerty:
FDA — OMEGA Letter: Interim Response, March 17, 2006
Publication Date
Date: March 17, 2006 Jay Davis, PresidentOmega Laboratories, Inc. RE: Request for Correction (Removal) of Information Found On the QIVD Section of the FDA Web Site Dear Mr. Davis:
NTP — Atrazine: HHS Response to RFC, May 25, 2005
Publication Date
Date: May 25, 2005 To Mr. Jim Tozzi, Center for Regulatory Effectiveness Dear Mr. Tozzi: From: National Institutes of Health, National Institute of Environmental Health Sciences
FDA — OMEGA Letter: Interim Response, January 17. 2006
Publication Date
Date: January 17. 2006 Jay Davis, President, Omega Laboratories, Inc. RE: Request for Correction (Removal) of Information Found On the OIVD Section of the FDA Web Site Dear Mr. Davis:
FDA — OMEGA Letter: Interim Response, November 18,2005
Publication Date
Date: November 18,2005 To: Jay Davis, President, Omega Laboratories, Inc. RE: Request for Correction (Removal) of Information Found On the OIVD Section of the FDA Web Site Dear Mr. Davis:
FDA — Menthol Cigarette Background Paper: Response to RFR
Publication Date
March 5, 2014 Mr. Ronald S. Milstein Senior Vice PresidentLegal and External AffairsGeneral Counsel and SecretaryLorillard, Inc.714 Green Valley RoadGreensboro, North Carolina 27408 Dear Mr. Milstein:
FDA — OMEGA Letter: Interim Response, July 22, 2005
Publication Date
Date: July 22, 2005 Jay Davis, President Omega Laboratories, Inc. 400 RE: Request for Correction (Removal) of Information Found On the OrVD Section of the FDA Web Site Dear Mr. Davis:
NTP — Anthraquinone Abstract: HHS Response to Rfr
Publication Date
September 8, 2003 Mr. Jerry A. Cook Technical Director Chemical Products Corporation Cartersville, Georgia 30120 Re: Request for Reconsideration submitted March 27, 2003 Dear Mr. Cook:
CDC/ATSDR — Formaldehyde Levels: b.7. Interim Response
Publication Date
Betsy M. Natz Executive DirectorThe Fonnaldehyde Council, IncNorth Quincy Street, Suite 700Arlington, V A 22203 Dear Ms. Natz:
CDC/ATSDR — Formaldehyde Levels: b.6. Interim Response
Publication Date
Betsy M. Natz Executive Director Dear Ms. Natz: